Plant Name: Juncus effusus
Taxonomic Information:
Plant ID: NPO1150
Plant Latin Name: Juncus effusus
Taxonomy Genus: Juncus
Taxonomy Family: Juncaceae
Plant External Links:
NCBI TaxonomyDB:
13579
Plant-of-the-World-Online:
442917-1
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
TCMMedicinal Functions:
Antiphlogistic; Depurative; Diuretic; Febrifuge; Lenitive; Lithontripic; Pectoral; Sedative
Geographical Distribution:
Canada; Afghanistan; Madagascar; Italy; Peru; Costa Rica; Cambodia; France; Ethiopia; Netherlands; Ireland; Bolivia; Norway; Ecuador; Australia; Iran; Algeria; El Salvador; Iceland; Venezuela; Guatemala; Zimbabwe; China; Belgium; Germany; Haiti; Iraq; Tanzania; Spain; Ukraine; Georgia; Uganda; Denmark; Poland; Finland; Turkey; Mauritius; Morocco; Sweden; Belarus; Kenya; Switzerland; New Zealand; Russia; Bulgaria; United States; Romania; Albania; Honduras; Portugal; Mexico; Tunisia; South Africa; India; United Kingdom; Austria; Rwanda; Colombia; Greece; Burundi; Hungary; Taiwan; Cyprus
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| KCNH2; | |
| EBP; ALOX15; ALDH1A1; HPGD; MGLL; | |
| JAK2; | |
| ESR1; ESR2; | |
| MDM2; | |
| HTT; LMNA; SIGMAR1; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | EBP | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase | Q15125 | CHEMBL4931 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MGLL | Monoglyceride lipase | Q99685 | CHEMBL4191 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
| Protein Kinase | JAK2 | Tyrosine-protein kinase JAK2 | O60674 | CHEMBL2971 |
| Transferase | MDM2 | p53-binding protein Mdm-2 | Q00987 | CHEMBL5023 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 5.783E-07 | 4.826E-03 | HPGD, JAK2, MDM2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.629E-07 | 4.826E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.649E-07 | 4.826E-03 | ESR1, ESR2, HPGD, HTT, JAK2, KCNH2, L3MBTL1, MDM2, MGLL |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.075E-06 | 1.269E-04 | MAPK1, JAK2, ESR1, ESR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.858E-06 | 2.276E-04 | HSP90AA1, MAPK1, ESR1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.234E-04 | 4.853E-03 | HSP90AA1, MDM2, MAPK1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.573E-04 | 5.587E-03 | EBP, ALOX15, ALDH1A1, ALOX12, CYP3A4, HSD17B10, MGLL |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.436E-04 | 5.587E-03 | ALOX15, MAPK1, ALOX12 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 4.764E-04 | 7.027E-03 | HSP90AA1, MDM2, MAPK1, JAK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.841E-04 | 5.587E-03 | MDM2, MAPK1, ESR1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 7.972E-04 | 1.045E-02 | MAPK1, MAPT, HSD17B10 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.606E-04 | 7.027E-03 | ALOX15, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.228E-04 | 1.089E-02 | MDM2, MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | MDM2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Anemia | D50-D64 | JAK2; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; JAK2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MDM2; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | EBP; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | JAK2; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | MDM2; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; JAK2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | JAK2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; MDM2; |
| C00-D49: Neoplasms | Polycythemia vera | D45 | JAK2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; JAK2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MDM2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | JAK2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Myeloproliferative disorder | C94.6 | JAK2; |
| NA: NA | Myeloproliferative neoplasm | NA | JAK2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; JAK2; MDM2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
